{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:32:52Z","timestamp":1769628772255,"version":"3.49.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"DOI":"10.1097\/qai.0b013e3182928eea","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T12:27:26Z","timestamp":1364560046000},"page":"201-208","source":"Crossref","is-referenced-by-count":21,"title":["High-Dose Valacyclovir Decreases Plasma HIV-1 RNA More Than Standard-Dose Acyclovir in Persons Coinfected with HIV-1 and HSV-2"],"prefix":"10.1097","volume":"63","author":[{"given":"Tara","family":"Perti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misty","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Diem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negusse","family":"Ocbamichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meei-Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Selke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210131","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":". Prevention of HIV-1 infection with early antiretroviral therapy.","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-9-20210131","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":". Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.","volume":"342","author":"Quinn","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-9-20210131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.aids.0000196566.40702.28","article-title":". Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda.","volume":"20","author":"Bunnell","year":"2006","journal-title":"AIDS"},{"key":"R4-9-20210131","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/S0140-6736(10)60705-2","article-title":". Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.","volume":"375","author":"Donnell","year":"2010","journal-title":"Lancet"},{"key":"R5-9-20210131","doi-asserted-by":"crossref","first-page":"c2205","DOI":"10.1136\/bmj.c2205","article-title":". Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study.","volume":"340","author":"Del Romero","year":"2010","journal-title":"BMJ"},{"key":"R6-9-20210131","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAD.0b013e3283437c2b","article-title":". HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy.","volume":"25","author":"Reynolds","year":"2011","journal-title":"AIDS"},{"key":"R8-9-20210131","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa062607","article-title":". Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.","volume":"356","author":"Nagot","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-9-20210131","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1086\/593214","article-title":". Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.","volume":"198","author":"Baeten","year":"2008","journal-title":"J Infect Dis"},{"key":"R10-9-20210131","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa0904849","article-title":". Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.","volume":"362","author":"Celum","year":"2010","journal-title":"N Engl J Med"},{"key":"R11-9-20210131","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QAD.0b013e32831db217","article-title":". Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.","volume":"23","author":"Delany","year":"2009","journal-title":"AIDS"},{"key":"R12-9-20210131","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e3181831832","article-title":". Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.","volume":"49","author":"Dunne","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-9-20210131","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1086\/522523","article-title":". Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.","volume":"196","author":"Zuckerman","year":"2007","journal-title":"J Infect Dis"},{"key":"R14-9-20210131","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/QAD.0b013e328347fa37","article-title":". Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2.","volume":"25","author":"Ludema","year":"2011","journal-title":"AIDS"},{"key":"R15-9-20210131","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1097\/QAD.0b013e3283491e3e","article-title":". The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.","volume":"25","author":"Barnabas","year":"2011","journal-title":"AIDS"},{"key":"R16-9-20210131","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(09)62038-9","article-title":". Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.","volume":"375","author":"Lingappa","year":"2010","journal-title":"Lancet"},{"key":"R17-9-20210131","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(12)70037-3","article-title":". Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.","volume":"12","author":"Reynolds","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R18-9-20210131","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/viro.2000.0667","article-title":". Herpes simplex virus infection induces replication of human immunodeficiency virus type 1.","volume":"278","author":"Moriuchi","year":"2000","journal-title":"Virology"},{"key":"R19-9-20210131","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1473-3099(08)70181-6","article-title":". Herpes simplex virus and HIV-1: deciphering viral synergy.","volume":"8","author":"Van de Perre","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R20-9-20210131","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2008.07.008","article-title":". Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.","volume":"4","author":"Lisco","year":"2008","journal-title":"Cell Host Microbe"},{"key":"R21-9-20210131","doi-asserted-by":"crossref","first-page":"31289","DOI":"10.1074\/jbc.C800188200","article-title":". The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.","volume":"283","author":"McMahon","year":"2008","journal-title":"J Biol Chem"},{"key":"R22-9-20210131","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/infdis\/jir649","article-title":". High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1HSV-2 coinfected persons: a randomized, crossover trial.","volume":"204","author":"Mugwanya","year":"2011","journal-title":"J Infect Dis"},{"key":"R23-9-20210131","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/JCM.26.4.662-667.1988","article-title":". Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.","volume":"26","author":"Ashley","year":"1988","journal-title":"J Clin Microbiol"},{"key":"R24-9-20210131","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":". Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"key":"R25-9-20210131","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QAI.0b013e3181d91322","article-title":". Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults.","volume":"54","author":"Mark","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-9-20210131","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/424519","article-title":". Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.","volume":"190","author":"Gupta","year":"2004","journal-title":"J Infect Dis"},{"key":"R27-9-20210131","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1128\/JCM.40.7.2609-2611.2002","article-title":". Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR.","volume":"40","author":"Jerome","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R28-9-20210131","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/JCM.42.3.1142-1148.2004","article-title":". Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.","volume":"42","author":"Boeckh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"R29-9-20210131","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/JCM.01405-06","article-title":". Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa.","volume":"45","author":"Magaret","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R30-9-20210131","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/01.qai.0000209895.82255.08","article-title":". Lower genitourinary tract sources of seminal HIV.","volume":"41","author":"Coombs","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-9-20210131","first-page":"8","article-title":"Sample size for a binomial rate with autocorrelation.","volume":"3","author":"Magaret","year":"2011","journal-title":"Stat Commun Infect Dis"},{"key":"R32-9-20210131","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"R33-9-20210131","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00002030-200305230-00006","article-title":". Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.","volume":"17","author":"Louie","year":"2003","journal-title":"AIDS"},{"key":"R34-9-20210131","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":". Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"R35-9-20210131","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":". HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"R36-9-20210131","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/0956462021924550","article-title":". Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials.","volume":"13","author":"Conant","year":"2002","journal-title":"Int J STD AIDS"},{"key":"R37-9-20210131","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/sti.2008.031153","article-title":". A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.","volume":"84","author":"Cowan","year":"2008","journal-title":"Sex Transm Infect"},{"key":"R38-9-20210131","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/sti.2010.048496","article-title":". Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania.","volume":"87","author":"Tanton","year":"2011","journal-title":"Sex Transm Infect"},{"key":"R39-9-20210131","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1128\/JVI.02423-10","article-title":". Consistent inhibition of HIV-1 replication in CD4 T cells by acyclovir without detection of human herpesviruses.","volume":"85","author":"McMahon","year":"2011","journal-title":"J Virol"},{"key":"R40-9-20210131","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":". Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. North American HIV working party.","volume":"333","author":"Eron","year":"1995","journal-title":"N Engl J Med"},{"key":"R41-9-20210131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/infdis\/jiq013","article-title":". Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1HSV-2 dually infected persons.","volume":"203","author":"Baeten","year":"2011","journal-title":"J Infect Dis"},{"key":"R42-9-20210131","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1086\/655662","article-title":". Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.","volume":"202","author":"Kim","year":"2010","journal-title":"J Infect Dis"},{"key":"R43-9-20210131","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1086\/345771","article-title":". Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.","volume":"186","author":"Schacker","year":"2002","journal-title":"J Infect Dis"},{"key":"R44-9-20210131","doi-asserted-by":"crossref","first-page":"e12598","DOI":"10.1371\/journal.pone.0012598","article-title":". Estimating the impact of HIV-1 plasma RNA reductions on heterosexual HIV-1 transmission risk.","volume":"5","author":"Lingappa","year":"2010","journal-title":"PLoS One"},{"key":"R46-9-20210131","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/mi.2012.1","article-title":". Mucosal correlates of isolated HIV semen shedding during effective antiretroviral therapy.","volume":"5","author":"Sheth","year":"2012","journal-title":"Mucosal Immunol"},{"key":"R48-9-20210131","first-page":"389","article-title":". Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV cost and services utilization study.","volume":"35","author":"Andersen","year":"2000","journal-title":"Health Serv Res"},{"key":"R49-9-20210131","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.genhosppsych.2007.03.008","article-title":". Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use.","volume":"29","author":"Himelhoch","year":"2007","journal-title":"Gen Hosp Psychiatry"},{"key":"R50-9-20210131","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/cid\/cis750","article-title":". The effect of a universal antiretroviral therapy recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500L in a public health setting.","volume":"55","author":"Geng","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182928eea","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:01:02Z","timestamp":1620972062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201306010-00009"}},"subtitle":["A Randomized Crossover Trial"],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182928eea","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}